Blackhawk Capital Partners LLC. Invests $245,000 in AstraZeneca PLC (NASDAQ:AZN)

Blackhawk Capital Partners LLC. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 3,151 shares of the company’s stock, valued at approximately $245,000.

Several other large investors have also modified their holdings of AZN. Stratos Wealth Advisors LLC boosted its position in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares during the last quarter. Bruce G. Allen Investments LLC lifted its stake in shares of AstraZeneca by 19.1% during the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after purchasing an additional 138 shares in the last quarter. Carnegie Investment Counsel grew its stake in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after buying an additional 138 shares in the last quarter. Crumly & Associates Inc. raised its holdings in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN stock opened at $63.20 on Thursday. The firm has a market cap of $195.96 billion, a P/E ratio of 30.24, a P/E/G ratio of 1.17 and a beta of 0.47. The firm has a fifty day moving average of $73.99 and a two-hundred day moving average of $77.95. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm earned $0.87 earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, research analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AZN shares. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.